ISA-2011B is a PIP5Kα (Phosphatidylinositol-4-phosphate 5-kinase-α) inhibitor. The overexpression of PIP5K1α is associated with poor prognosis in prostate cancer and correlates with an elevated level of the androgen receptor. ISA-2011B significantly inhibits growth of tumor cells in xenograft mice, which is mediated by targeting PIP5K1α-associated PI3K/AKT and the downstream survival, proliferation, and invasion pathways. PIP5K1α has high potential as a drug target, and compound ISA-2011B is interesting for further development of targeted cancer therapy.
CAS 1395347-24-6 MFCD495347246
化学结构图
SMILES: CN1CC(=O)N2[C@@H](Cc3cc4c(cc3[C@H]2c2c[nH]c3ccc(Cl)cc23)OCO4)C1=O
化学属性
| Mol. Weight | 423.85 |
|---|---|
| Appearance | Solid powder |
| Solubility | Soluble in DMSO, not in water |
别名和识别编码
| Chemical Name | ISA-2011B is a PIP5Kα (Phosphatidylinositol-4-phosphate 5-kinase-α) inhibitor. The overexpression of PIP5K1α is associated with poor prognosis in prostate cancer and correlates with an elevated level of the androgen receptor. ISA-2011B significantly inhibits growth of tumor cells in xenograft mice, which is mediated by targeting PIP5K1α-associated PI3K/AKT and the downstream survival, proliferation, and invasion pathways. PIP5K1α has high potential as a drug target, and compound ISA-2011B is interesting for further development of targeted cancer therapy. |
|---|---|
| Formula | C22H18ClN3O4 |
| Synonym | ISA2011B; ISA 2011B; ISA-2011B; ISA2011-B; ISA 2011-B; ISA-2011-B. |
| IUPAC Name | (5S,10aS)-5-(5-chloro-1H-indol-3-yl)-9-methyl-8,9,10a,11-tetrahydro-5H-[1,3]dioxolo[4,5-g]pyrazino[1,2-b]isoquinoline-7,10-dione |
| InChIKey | FSEZESVJDPKRDS-UWJYYQICSA-N |
| InChI | InChI=1S/C22H18ClN3O4/c1-25-9-20(27)26-17(22(25)28)4-11-5-18-19(30-10-29-18)7-13(11)21(26)15-8-24-16-3-2-12(23)6-14(15)16/h2-3,5-8,17,21,24H,4,9-10H2,1H3/t17-,21-/m0/s1 |
| Canonical SMILES | O=C(N1[C@H](C2=CNC3=C2C=C(Cl)C=C3)C4=C(C=C5C(OCO5)=C4)C[C@]16[H])CN(C)C6=O |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
产品应用
- ISA-2011B is a PIP5Kα (Phosphatidylinositol-4-phosphate 5-kinase-α) inhibitor. The overexpression of PIP5K1α is associated with poor prognosis in prostate cancer and correlates with an elevated level of the androgen receptor. ISA-2011B significantly inhibits growth of tumor cells in xenograft mice, which is mediated by targeting PIP5K1α-associated PI3K/AKT and the downstream survival, proliferation, and invasion pathways. PIP5K1α has high potential as a drug target, and compound ISA-2011B is interesting for further development of targeted cancer therapy.
